IPM Take
Europe’s cholesterol supplement market is approaching a regulatory turning point.
The European Commission restricted monacolins from red yeast rice in 2022, prohibiting products that provide 3 mg or more per recommended daily portion. In 2025, the European Food Safety Authority (EFSA) concluded that additional scientific evidence still could not establish a safe intake below that threshold. A Commission proposal for full prohibition subsequently received a favourable opinion from Member States in May 2026.
For supplement manufacturers, that creates an obvious commercial problem.
For cardiology, however, it raises a more fundamental question: what level of evidence should justify replacing one cholesterol-lowering ingredient with another?
An article published by Nutraceutical Business Review on 30 September promotes Kalita, a whole-bergamot phytocomplex developed by Giellepi, as a potential response to the changing market. The article is explicitly labelled Promoted Content and emphasises a broader, multi-target approach to cardiometabolic health.
There is clinical research behind the ingredient. A 90-participant, placebo-controlled study published in 2023 reported improvements in LDL cholesterol and several metabolic markers following 12 weeks of supplementation.
But improved biomarkers are not the same as preventing myocardial infarction, stroke or cardiovascular death.
That distinction matters especially now. The 2025 ESC/EAS dyslipidaemia guidance does not recommend supplements lacking documented safety and substantial LDL-lowering efficacy for cardiovascular prevention. The 2026 ACC/AHA guideline takes a similarly restrictive position toward dietary supplements for lipid lowering.
The next generation of cardiometabolic nutraceuticals may offer biologically interesting ingredients. It still has to demonstrate meaningful clinical value.
Executive Summary
The European regulatory response to red yeast rice monacolins follows longstanding safety concerns, particularly involving monacolin K, which is chemically identical to lovastatin in its lactone form.
Under Regulation (EU) 2022/860, products containing 3 mg or more of red yeast rice monacolins per recommended daily portion were prohibited, while lower-dose products became subject to specific labelling requirements and regulatory scrutiny. EFSA’s 2025 reassessment concluded that neither the existing nor newly submitted evidence could establish a daily intake free from safety concerns.
In May 2026, Member States issued a favourable opinion on a Commission proposal to prohibit monacolins from red yeast rice in food. The draft included a proposed 12-month transition period for products lawfully placed on the market. The committee’s decision supports progression of the measure but should not itself be described as a ban already in force.
In parallel, manufacturers are exploring non-monacolin approaches, including bergamot extracts containing flavonoids, polyphenols and other constituents.
One randomised clinical trial involving the phytocomplex marketed as Kalita assessed 90 adults with features of metabolic syndrome. At the higher tested dose of 700 mg daily, LDL cholesterol decreased by an average of 17.7% from baseline after 12 weeks, with a statistically significant difference compared with placebo. The study also reported improvements in triglycerides and insulin-resistance markers.
However, the trial was small, short and focused on surrogate outcomes. It did not demonstrate reduced cardiovascular events or establish equivalence to statins or monacolin-containing supplements.
Why it matters
- HTA bodies: The growth of botanical cardiometabolic products reinforces the need to distinguish changes in lipid biomarkers from proven reductions in cardiovascular morbidity and mortality. Small trials may support further research without establishing therapeutic equivalence or long-term clinical benefit.
- Payers: Supplements generally operate outside conventional pharmaceutical reimbursement pathways, but patients may use them instead of prescribed lipid-lowering treatment. Clear evidence communication is important to prevent substitution for therapies with established outcome benefits.
- Industry / innovation partners: A potential full EU prohibition would create opportunities for alternative ingredient development, but commercial differentiation based on complex formulations or multi-target activity will not remove the need for reproducible efficacy, robust safety data and compliant health claims.
Europe’s cholesterol supplement market is facing a regulatory reckoning.
For years, red yeast rice was positioned as a natural approach to cholesterol management. Its best-known active constituent, monacolin K, inhibits HMG-CoA reductase, the same enzyme targeted by statins. In its lactone form, monacolin K is chemically identical to lovastatin.
That pharmacological activity also explains the regulatory problem.
In 2022, the European Commission prohibited red yeast rice supplements providing 3 mg or more of monacolins per recommended daily portion, following concerns about muscle and liver toxicity. Products below that threshold remained permitted under specific conditions, but their safety remained under scrutiny.
From restriction toward prohibition
EFSA’s reassessment, published in 2025, strengthened the case for further action.
After reviewing additional safety data, clinical studies and adverse-event reports, EFSA concluded that severe reactions, including rhabdomyolysis and liver injury, could occur at monacolin K intakes as low as 3 mg daily. It also found that the available evidence was insufficient to establish a safe intake below that level.
The European Commission subsequently proposed moving red yeast rice monacolins into the category of substances prohibited in foods, including food supplements.
In May 2026, the Standing Committee on Plants, Animals, Food and Feed issued a favourable opinion on the proposal. Discussions included the proposed 12-month transition period for products already lawfully marketed, alongside requests from some Member States for additional time or a less restrictive approach.
The market is therefore preparing for a much more restrictive environment, although the committee vote alone does not make the proposed prohibition legally effective.
Bergamot enters the conversation
As manufacturers reconsider monacolin-containing products, botanical ingredients are attracting renewed commercial attention.
One example is Kalita, a standardised bergamot phytocomplex marketed by Giellepi and highlighted in a 30 September article in Nutraceutical Business Review.
Bergamot (Citrus bergamia), traditionally cultivated in Southern Italy, contains polyphenols, flavonoids and other compounds that have been investigated for their potential effects on lipid metabolism, insulin sensitivity and inflammatory pathways.
The promoted article positions Kalita as a multi-target strategy rather than a direct replacement for monacolin K, emphasising the potential value of combining several naturally occurring bioactive constituents.
Unlike a purely theoretical ingredient concept, the formulation has been evaluated in a human clinical trial.
A randomised, double-blind, placebo-controlled study published in Archives of Medical Science in 2023 enrolled 90 adults with features of metabolic syndrome. Participants received either 350 mg or 700 mg of the standardised bergamot extract daily, or placebo, for 12 weeks.
In the higher-dose group, investigators reported statistically significant improvements in several metabolic parameters compared with placebo. From baseline, LDL cholesterol fell by an average of 17.7%, triglycerides by 16.6% and the HOMA-IR insulin-resistance index by 12.2%.
Both doses showed improvements in some measures of atherogenic dyslipidaemia and insulin sensitivity.
These are encouraging findings, but they require careful interpretation.
The trial excluded patients with established atherosclerotic cardiovascular disease, diabetes, LDL cholesterol above 190 mg/dL and elevated estimated cardiovascular risk. Participants using lipid-lowering medicines were also excluded.
Consequently, the results cannot establish whether the ingredient provides additional benefit alongside standard cardiovascular medicines or whether it is effective in higher-risk patients.
The study was also limited to 12 weeks, involved just 30 participants per treatment arm and assessed biomarkers rather than major clinical outcomes.
No reduction in heart attacks, strokes, cardiovascular mortality or long-term disease progression was demonstrated.
A supplement is not automatically a treatment alternative
The distinction between improving laboratory markers and preventing cardiovascular events is fundamental.
A sustained reduction in LDL cholesterol through validated therapeutic approaches is an established strategy for reducing atherosclerotic cardiovascular risk. But a relatively short trial showing lower LDL cholesterol with a particular supplement does not, by itself, demonstrate equivalent long-term clinical benefit.
Current professional guidance reflects that distinction.
The 2025 ESC/EAS focused update on dyslipidaemia management does not recommend dietary supplements or vitamins lacking documented safety and significant LDL-lowering efficacy to reduce atherosclerotic cardiovascular risk. The guideline also notes that convincing cardiovascular outcome evidence for red yeast rice preparations has been lacking.
Similarly, the 2026 ACC/AHA dyslipidaemia guideline recommends against using dietary supplements to lower LDL cholesterol or triglycerides in people with dyslipidaemia, citing limited and inconsistent evidence and uncertain cardiovascular benefit.
For bergamot products, the immediate research priorities are therefore clear: larger randomised studies, longer safety follow-up, evaluation alongside standard therapies and evidence that changes in biomarkers translate into meaningful clinical benefit.
The composition and standardisation of different bergamot extracts will also matter. Results obtained with one proprietary formulation should not automatically be applied to every bergamot-containing supplement.
A turning point for cardiometabolic nutraceuticals
The changing European rules could accelerate reformulation and investment in plant-derived ingredients, probiotics and other approaches to metabolic health.
But the pressure to replace monacolins also creates an important risk: that commercial demand for substitutes moves faster than the evidence supporting them.
The promoted Kalita article illustrates both sides of this transition. It identifies a potentially interesting ingredient with published human data, but its commercial framing necessarily warrants scrutiny. The existence of a clinical study does not establish cardiovascular protection, therapeutic equivalence or long-term safety.
For regulators, manufacturers and clinicians, the next stage should be defined less by the search for a replacement ingredient and more by the quality of the evidence behind it.
Europe’s move away from red yeast rice monacolins is being driven by safety concerns. The next generation of cholesterol supplements will need to compete on evidence, not simply on the promise of being natural.
